Characterization of the Plasma Biomarker (24HC) in children with DEE
Research type
Research Study
Full title
Multi-Center Characterization of the Plasma Biomarker, 24s-hydroxycholesterol (24HC) in children with Development and/or Epileptic Encephalopathies
IRAS ID
253422
Contact name
Helen Cross
Contact email
Sponsor organisation
Ovid Therapeutics
Duration of Study in the UK
1 years, 0 months, 13 days
Research summary
This is a study in 50 male or female children aged between 2 and 12 years with a documented history of Developmental and Epileptic Encephalopathies (DEE). The study will be performed in the US and in the UK. An enzyme called CH24H, converts cholesterol in the brain to 24HC. Research shows that levels of 24HC decrease with age and lower levels of 24HC are reported in neurodegenerative disorders. Research is needed to determined how lower levels of 24HC are related to epilepsy disorders.
In this study a blood sample will be drawn from each subject to measure cholesterol levels and those levels will be compared to the seizure frequency in the
children diagnosed with DEE.REC name
London - Central Research Ethics Committee
REC reference
18/LO/2190
Date of REC Opinion
15 Jan 2019
REC opinion
Further Information Favourable Opinion